Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Astellas Pharma Inc | 18 |
| 2 | Mallinckrodt PLC | 5 |
| 3 | Daiichi Sankyo Co Ltd | 4 |
| 4 | Emory University | 2 |
Where innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 25 |
| 2 | A61P | Therapeutic activity (drug indications) | 22 |
| 3 | C07D | Heterocyclic compounds | 8 |
| 4 | Y02P | Climate change mitigation: production | 5 |
| 5 | C07F | Organometallic compounds | 4 |
| 6 | C07H | Sugars and derivatives | 3 |
| 7 | A61L | Sterilising / disinfecting materials | 2 |
| 8 | B01D | 2 | |
| 9 | B01J | Chemical/physical processes (e.g. catalysts) | 2 |
| 10 | C07C | Acyclic and carbocyclic compounds | 2 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Aerosol compositions | 2002 | Astellas Pharma Inc | 87 |
| Pharmaceutical composition | 2002 | Astellas Pharma Inc | 63 |
| Medicinal composition | 2002 | Astellas Pharma Inc | 58 |
| Sustained release formulations containing tacrolimus | 2003 | Astellas Pharma Inc | 55 |
| Use of macrolide compounds for the treatment of dry eye | 2005 | Mallinckrodt PLC | 47 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 572 |
| 2017 | 548 |
| 2018 | 547 |
| 2019 | 582 |
| 2020 | 568 |
| 2021 | 511 |
| 2022 | 502 |
| 2023 | 449 |
| 2024 | 402 |
| 2025 | 144 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | John J. Fung | University of Pittsburgh | 283 |
| 2 | Thomas E. Starzl | University of Pittsburgh | 243 |
| 3 | Satoru Todo | University of Pittsburgh | 85 |
| 4 | Ron Shapiro | University of Pittsburgh | 67 |
| 5 | Dennis A. Hesselink | Erasmus MC | 62 |
| 6 | Andreas G. Tzakis | University of Miami | 60 |
| 7 | Dirk Kuypers | KU Leuven | 59 |
| 8 | Raman Venkataramanan | University of Pittsburgh | 53 |
| 9 | Teun van Gelder | Erasmus MC | 47 |
| 10 | Lionel Rostaing | Hôpital Rangueil | 47 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen | 2000 | 5293 | Renal Transplantation Outcomes and Treatments |
| Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes | 1991 | 4167 | Signaling Pathways in Disease |
| Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders | 2011 | 3686 | Telomeres, Telomerase, and Senescence |
| Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model | 2007 | 2314 | Neuroscience and Neuropharmacology Research |
| The mechanism of action of cyclosporin A and FK506 | 1992 | 2152 | Viral Infections and Immunology Research |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of Prograf?
Which companies hold the most patents for Prograf?
What types of formulations have been patented for Prograf?
Which researchers have published the most papers on Prograf?
How has research activity on Prograf changed in recent years?